CN1267117C - 一种治疗跌打损伤、胸胁疼痛的药物组合物及其制备方法 - Google Patents
一种治疗跌打损伤、胸胁疼痛的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN1267117C CN1267117C CN 03131143 CN03131143A CN1267117C CN 1267117 C CN1267117 C CN 1267117C CN 03131143 CN03131143 CN 03131143 CN 03131143 A CN03131143 A CN 03131143A CN 1267117 C CN1267117 C CN 1267117C
- Authority
- CN
- China
- Prior art keywords
- solution
- reference substance
- methanol
- add
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 47
- 230000036407 pain Effects 0.000 title claims abstract description 21
- 208000014674 injury Diseases 0.000 title claims abstract description 16
- 230000008736 traumatic injury Effects 0.000 title claims abstract description 11
- 239000000203 mixture Substances 0.000 title abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 51
- 239000003814 drug Substances 0.000 claims abstract description 46
- 210000000582 semen Anatomy 0.000 claims abstract description 12
- 238000003908 quality control method Methods 0.000 claims abstract description 11
- 241000218176 Corydalis Species 0.000 claims abstract description 10
- 241000628997 Flos Species 0.000 claims abstract description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 159
- 239000007788 liquid Substances 0.000 claims description 113
- 238000012360 testing method Methods 0.000 claims description 108
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 92
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 83
- 239000013558 reference substance Substances 0.000 claims description 56
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 43
- 239000000047 product Substances 0.000 claims description 35
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 30
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 30
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 claims description 29
- 239000010282 Emodin Substances 0.000 claims description 29
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 claims description 29
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 claims description 29
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 claims description 29
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 claims description 29
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 claims description 29
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 claims description 29
- 239000000706 filtrate Substances 0.000 claims description 28
- 229960004756 ethanol Drugs 0.000 claims description 27
- 238000004809 thin layer chromatography Methods 0.000 claims description 27
- 239000002775 capsule Substances 0.000 claims description 24
- 239000002904 solvent Substances 0.000 claims description 23
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 21
- 239000000284 extract Substances 0.000 claims description 21
- 239000000741 silica gel Substances 0.000 claims description 21
- 229910002027 silica gel Inorganic materials 0.000 claims description 21
- 238000000605 extraction Methods 0.000 claims description 20
- 230000008569 process Effects 0.000 claims description 18
- 239000002131 composite material Substances 0.000 claims description 17
- XRIVRYRXJYCJTQ-UHFFFAOYSA-N benzene;ethyl acetate;formic acid Chemical compound OC=O.CCOC(C)=O.C1=CC=CC=C1 XRIVRYRXJYCJTQ-UHFFFAOYSA-N 0.000 claims description 16
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 16
- 238000012546 transfer Methods 0.000 claims description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 15
- 238000005406 washing Methods 0.000 claims description 15
- 239000008187 granular material Substances 0.000 claims description 13
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 10
- 239000000890 drug combination Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 239000000796 flavoring agent Substances 0.000 claims description 6
- 235000019634 flavors Nutrition 0.000 claims description 6
- 230000007062 hydrolysis Effects 0.000 claims description 6
- 238000006460 hydrolysis reaction Methods 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 238000004064 recycling Methods 0.000 claims description 6
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- AEQDJSLRWYMAQI-UHFFFAOYSA-N Tetrahydropalmatine Natural products C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 claims description 5
- 229910021529 ammonia Inorganic materials 0.000 claims description 5
- ONPSRCNNSZSSMH-UHFFFAOYSA-N chloroform;hexane;methanol Chemical compound OC.ClC(Cl)Cl.CCCCCC ONPSRCNNSZSSMH-UHFFFAOYSA-N 0.000 claims description 5
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims description 5
- 229940114124 ferulic acid Drugs 0.000 claims description 5
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims description 5
- 235000001785 ferulic acid Nutrition 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 229910052740 iodine Inorganic materials 0.000 claims description 5
- 239000011630 iodine Substances 0.000 claims description 5
- 239000008517 radix Trichosanthis Substances 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000000779 smoke Substances 0.000 claims description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- AEQDJSLRWYMAQI-KRWDZBQOSA-N tetrahydropalmatine Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3C[C@H]2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-KRWDZBQOSA-N 0.000 claims description 5
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims description 5
- 239000000052 vinegar Substances 0.000 claims description 5
- 235000021419 vinegar Nutrition 0.000 claims description 5
- 238000003556 assay Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 3
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 3
- 238000012850 discrimination method Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 241000202807 Glycyrrhiza Species 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 238000002481 ethanol extraction Methods 0.000 abstract 1
- 238000005259 measurement Methods 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 37
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 37
- 210000004369 blood Anatomy 0.000 description 26
- 239000008280 blood Substances 0.000 description 26
- 235000003143 Panax notoginseng Nutrition 0.000 description 25
- 241000180649 Panax notoginseng Species 0.000 description 25
- 241000700159 Rattus Species 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 19
- 239000012567 medical material Substances 0.000 description 18
- 230000006378 damage Effects 0.000 description 15
- 230000017531 blood circulation Effects 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 210000002381 plasma Anatomy 0.000 description 12
- 208000027418 Wounds and injury Diseases 0.000 description 11
- 238000011534 incubation Methods 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 210000004204 blood vessel Anatomy 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000013641 positive control Substances 0.000 description 9
- 206010053567 Coagulopathies Diseases 0.000 description 8
- 206010014080 Ecchymosis Diseases 0.000 description 8
- 108090000190 Thrombin Proteins 0.000 description 8
- 210000002565 arteriole Anatomy 0.000 description 8
- 230000035602 clotting Effects 0.000 description 8
- 230000008961 swelling Effects 0.000 description 8
- 229960004072 thrombin Drugs 0.000 description 8
- 210000000264 venule Anatomy 0.000 description 8
- 208000034656 Contusions Diseases 0.000 description 7
- 208000007536 Thrombosis Diseases 0.000 description 7
- 206010052428 Wound Diseases 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 230000005611 electricity Effects 0.000 description 7
- 230000007794 irritation Effects 0.000 description 7
- 210000003141 lower extremity Anatomy 0.000 description 7
- 230000004089 microcirculation Effects 0.000 description 7
- 230000010412 perfusion Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 208000026137 Soft tissue injury Diseases 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 208000010392 Bone Fractures Diseases 0.000 description 5
- 206010018852 Haematoma Diseases 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 210000000038 chest Anatomy 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 229940127219 anticoagulant drug Drugs 0.000 description 4
- 235000010418 carrageenan Nutrition 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- 230000009519 contusion Effects 0.000 description 4
- 210000005069 ears Anatomy 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000010100 anticoagulation Effects 0.000 description 3
- 229940026189 antimony potassium tartrate Drugs 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- WBTCZEPSIIFINA-MSFWTACDSA-J dipotassium;antimony(3+);(2r,3r)-2,3-dioxidobutanedioate;trihydrate Chemical compound O.O.O.[K+].[K+].[Sb+3].[Sb+3].[O-]C(=O)[C@H]([O-])[C@@H]([O-])C([O-])=O.[O-]C(=O)[C@H]([O-])[C@@H]([O-])C([O-])=O WBTCZEPSIIFINA-MSFWTACDSA-J 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 240000006409 Acacia auriculiformis Species 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 206010014025 Ear swelling Diseases 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010061245 Internal injury Diseases 0.000 description 2
- 206010024453 Ligament sprain Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 208000010040 Sprains and Strains Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 208000034526 bruise Diseases 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 238000005485 electric heating Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000002389 essential drug Substances 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000003118 histopathologic effect Effects 0.000 description 2
- 239000003230 hygroscopic agent Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- FXNDIJDIPNCZQJ-UHFFFAOYSA-N 2,4,4-trimethylpent-1-ene Chemical compound CC(=C)CC(C)(C)C FXNDIJDIPNCZQJ-UHFFFAOYSA-N 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 206010002953 Aphonia Diseases 0.000 description 1
- 208000007333 Brain Concussion Diseases 0.000 description 1
- 208000033386 Buerger disease Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241001147468 Chondrus ocellatus Species 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015967 Eye swelling Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 206010019027 Haemothorax Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229920005479 Lucite® Polymers 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 206010054974 Pelvic haematoma Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000002667 Subdural Hematoma Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 206010044546 Traumatic ulcer Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010071504 Wound haematoma Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- AUJJPYKPIQVRDH-UHFFFAOYSA-N antimony potassium Chemical compound [K].[Sb] AUJJPYKPIQVRDH-UHFFFAOYSA-N 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000000142 dyskinetic effect Effects 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000001037 metacarpus Anatomy 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 201000003144 pneumothorax Diseases 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- IIQJBVZYLIIMND-UHFFFAOYSA-J potassium;antimony(3+);2,3-dihydroxybutanedioate Chemical compound [K+].[Sb+3].[O-]C(=O)C(O)C(O)C([O-])=O.[O-]C(=O)C(O)C(O)C([O-])=O IIQJBVZYLIIMND-UHFFFAOYSA-J 0.000 description 1
- 238000005381 potential energy Methods 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- ZNCPFRVNHGOPAG-UHFFFAOYSA-L sodium oxalate Chemical compound [Na+].[Na+].[O-]C(=O)C([O-])=O ZNCPFRVNHGOPAG-UHFFFAOYSA-L 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- GTHUJPJMPAQNJI-UHFFFAOYSA-H tricalcium sulfuric acid diphosphate Chemical compound P(=O)([O-])([O-])[O-].[Ca+2].S(O)(O)(=O)=O.P(=O)([O-])([O-])[O-].[Ca+2].[Ca+2] GTHUJPJMPAQNJI-UHFFFAOYSA-H 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
组别 | n | 剂量(g/kg) | 潜伏期(S, X±SD) | 扭体次数( X±SD) |
NS | 10 | 127.9±59.9 | 16.1±6.1 | |
三七液 | 10 | 3 | 236.5±24.3*** | 9.6±2.3*** |
伤痛液 | 10 | 20 | 262.7±45.6*** | 7.7±4.7*** |
10 | 10 | 219.3±21.2*** | 10.2±2.3*** | |
10 | 5 | 152.3±26.9* | 12.7±2.7* |
组别 | n | 剂量(g/kg) | 潜伏期(S, X±SD) | |
给药前 | 给药后 | |||
NS | 10 | 8.5±1.6 | 6.8±2.5△ | |
三七液 | 10 | 3 | 9.6±2.3* | 56.4±12.7△△△ *** |
伤痛液 | 10 | 20 | 8.8±2.3* | 72.3±23.6△△△ *** |
10 | 10 | 9.2±3.0* | 46.8±11.4△△△ *** | |
10 | 5 | 8.4±2.3* | 47.5±11.1△△△ *** |
组别 | n | 剂量(g/kg) | 致炎前足跖厚度(mm,x±SD) | 足跖肿胀率(%, X±SD) | ||
致炎后1h | 3h | 6h | ||||
NS | 8 | 2.898±0.226 | 36.4±9.4 | 49.7±12.8 | 36.7±10.7 | |
三七液 | 8 | 3 | 2.690±0.153 | 26.2±8.4** | 42.8±11.4* | 31.6±9.1* |
伤痛液 | 8 | 20 | 2.737±0.164 | 23.3±8.1*** | 35.1±7.8*** | 23.9±6.8*** |
8 | 10 | 2.946±0.307 | 27.7±7.4*** | 37.3±9.2*** | 27.2±8.5*** | |
8 | 5 | 2.769±0.240 | 28.0±6.7*** | 39.8±7.7* | 29.5±6.3** |
组别 | n | 剂量(g/kg) | 左耳片重(mg, x±SD) | 右耳片重(mg, x±SD) | 炎耳肿胀率(%, X±SD) |
NS | 10 | 16.9±1.4 | 6.2±0.8 | 173.0±42.0 | |
三七液 | 10 | 3 | 14.2±2.4 | 6.0±0.7 | 135.2±23.6** |
伤痛液 | 10 | 20 | 12.8±1.7 | 6.8±1.0 | 89.9±21.7*** |
10 | 10 | 13.2±1.6 | 5.9±0.7 | 124.7±20.9*** | |
10 | 5 | 14.0±2.4 | 6.1±0.9 | 132.1±21.0** |
组别 | n | 剂量(g/kg) | CT(S, X±SD) |
NS | 10 | 75.6.±18.8 | |
三七液 | 10 | 3 | 283.5±42.3*** |
伤痛液 | 10 | 20 | 316.2±36.3*** |
10 | 10 | 199.7±22.2*** |
组别(g/kg×d) | n | 剂量(S, X±SD) | TT |
NS | 10 | 18.3.±5.8 | |
三七液 | 10 | 3×3 | 27.8±8.3*** |
伤痛液 | 10 | 20×3 | 29.3±7.5*** |
10 | 10×3 | 25.7±6.2** |
组别 | n | 剂量(g/kg×d) | RT(S, X±SD) |
NS | 10 | 32.7.±6.5 | |
三七液 | 10 | 3×3 | 55.8±13.2*** |
伤痛液 | 10 | 20×3 | 57.5±12.8*** |
10 | 10×3 | 49.3±9.3*** |
组别 | n | 剂量(g/kg×d) | 全血比粘度(切变率l/s. X±SD) 血浆比粘度 | ||||||
80 | 60 | 40 | 30 | 20 | (X±SD) | ||||
NS | 8 | 药前 | 7.40±0.68 | 8.18±1.21 | 8.50±0.79 | 9.60±1.26 | 10.50±1.20 | 1.75±0.21 | |
药后 | 7.65±0.36△ | 8.51±0.41△ | 9.09±0.43△ | 9.93±0.55△ | 10.67±0.71△ | 1.74±0.12△ | |||
通塞脉液 | 8 | 10×7 | 药前 | 7.37±0.88 | 8.10±0.92 | 9.03±1.06 | 9.97±1.14 | 10.73±1.10 | 1.65±0.05 |
药后 | 5.98±0.88△△△ *** | 6.44±0.94△△△ *** | 6.93±1.05△△△ *** | 7.57±1.14△△△ *** | 8.18±1.28△△△ *** | 1.60±0.06△ * | |||
伤痛液 | 8 | 20×7 | 药前 | 7.58±0.94 | 8.18±1.12 | 8.66±1.25 | 9.28±1.55 | 10.19±1.32 | 1.67±0.07 |
药后 | 6.16±0.58△△△ *** | 6.84±0.65△△△ *** | 7.43±0.78△△ *** | 8.45±0.76△△ *** | 8.83±0.94△△ *** | 1.61±0.08△ * | |||
8 | 10×7 | 药前 | 7.33±0.23 | 8.14±0.25 | 8.78±0.36 | 9.45±0.44 | 10.31±1.00 | 1.75±0.08 | |
药后 | 6.64±0.68△△△ ** | 7.49±0.70△△△ ** | 8.16±0.89△ ** | 8.83±1.08△ ** | 9.83±1.28△ * | 1.70±0.09△ * |
组别 | n | 剂量(g/kg) | 血栓重(mg, X±SD) | 抑制率(%) |
NS | 8 | 31.8±6.6 | ||
三七液 | 8 | 10 | 19.2±5.9*** | 39.6 |
伤痛液 | 8 | 20 | 17.6±5.3*** | 44.7 |
8 | 10 | 18.4±6.3*** | 42.1 | |
8 | 5 | 20.2±5.8*** | 36.5 |
组别 | n | 剂量(浓度,体积) | 给药前(g/min, X±SD) | 药后净增值(g/min, X±SD) | |||
5min | 10min | 15min | 20min | ||||
NS | 6 | 0.2ml | 40.2±8.1 | 3.0±1.50 | 2.5±1.4 | 2.0±1.3 | 1.3±0.5 |
通塞脉液 | 6 | 100%-0.2ml | 39.2±7.1* | 7.5±2.5*** | 9.0±2.2*** | 7.2±1.8*** | 5.8±2.2*** |
伤痛液 | 6 | 100%-0.2ml | 38.7±9.9* | 10.6±2.8*** | 13.0±3.2*** | 11.5±2.8*** | 7.6±1.5*** |
6 | 100%-0.1ml | 41.0±12.2* | 5.3±1.8** | 4.3±1.2** | 3.2±1.3* | 1.0±1.3* |
组别 | n | 剂量(g/kg) | 药前(um, X±SD) | 药后净增值(um, X±SD) | ||
10min | 20min | 40min | ||||
NS | 10 | 17.20±5.97 | 0.98±1.99 | 0.87±2.07 | 0.41±2.90 | |
通塞脉液 | 10 | 10 | 18.74±7.04* | 6.04±6.02** | 8.16±3.37*** | 9.01±8.56*** |
伤痛液 | 10 | 20 | 15.92±3.74* | 8.47±3.88*** | 9.44±5.51*** | 10.58±6.00*** |
10 | 10 | 15.92±1.99* | 7.05±5.91** | 7.73±3.96*** | 6.06±5.11** |
组别 | n | 剂量(g/kg) | 药前(um, X±SD) | 药后净增值(um, X±SD) | ||
10min | 20min | 40min | ||||
NS | 10 | 39.72±12.05 | 4.09±4.54 | 2.40±2.10 | 0.98±2.56 | |
通塞脉液 | 10 | 10 | 35.32±11.24* | 10.18±4.93** | 11.02±5.97*** | 10.12±5.90*** |
伤痛液 | 10 | 20 | 40.16±13.88* | 11.80±9.66** | 11.96±8.53*** | 11.84±9.51*** |
10 | 10 | 40.16±8.80* | 8.29±4.22** | 13.08±10.44** | 9.13±6.51*** |
组别 | n | 剂量(g/kg×d) | 血块重量(mg, X±SD) |
NS | 15 | 33.7±20.3 | |
三七液 | 15 | 3×7 | 17.3±12.5** |
伤痛液 | 15 | 20×7 | 18.8±13.8** |
15 | 10×7 | 19.9±16.1** | |
15 | 5×7 | 22.1±14.0* |
症候 | 程度轻重分级 | ||
不明显 | 明显 | 严重 | |
伤肢肿胀 | 0 | 1 | 2 |
局部瘀斑 | 0 | 1 | 2 |
运动障碍 | 0 | 1 | 2 |
组别 | 剂量(g/kg) | 损伤症候指数(X±SD) | ||
d1(n) | d3(n) | d6(n) | ||
NS | 5.5±0.5(12) | 3.2±0.4(9) | 2.0±0.1(6) | |
三七液 | 3 | 5.5±0.7*(12) | 1.8±0.4***(9) | 0.7±0.8**m*(6) |
伤痛液 | 20 | 5.8±0.4*(12) | 1.7±0.5***(9) | 0.3±0.5***(6) |
10 | 5.2±0.4*(12) | 2.2±0.4***(9) | 0.6±0.9**(6) |
水平 | 因素 | ||
加水倍数A | 煎煮时间(h)B | 煎煮次数C | |
1 | 8 | 0.5 | 1 |
2 | 2 | 0.75 | 2 |
3 | 15 | 1.0 | 3 |
组别 | 样品峰面积(Yi) | 点样量(μl) | 大黄素含量(mg) | 水平与因素的正交分析 | |||
1 | 9555.173 | 5 | 2.1328 | k1 | 11.5593 | 14.7504 | 12.7280 |
2 | 19584.870 | 5 | 4.4635 | k2 | 14.5375 | 15.8214 | 16.6261 |
3 | 21734.367 | 5 | 4.9630 | k3 | 21.1368 | 16.6618 | 17.8795 |
4 | 21466.702 | 5 | 4.9008 | A3 | B3 | C3 | |
5 | 22752.958 | 5 | 5.1997 | k1 | 3.8531 | 4.9168 | 4.2427 |
6 | 19470.832 | 5 | 4.4370 | k2 | 4.8458 | 5.2738 | 5.5420 |
7 | 33584.789 | 5 | 7.7168 | k3 | 7.0456 | 5.5539 | 5.9598 |
8 | 26877.669 | 5 | 6.1582 | R* | 3.1925 | 0.6371 | 1.7171 |
9 | 31626.788 | 5 | 7.2618 | A>B>C |
变异来源 | 离均差平方和 | 自由度 | 均方 | F | P |
A因素 | 16.02 | 2 | 8.010 | 22.25 | <0.05 |
B因素 | 0.61 | 2 | 0.305 | 0.847 | >0.05 |
C因素 | 4.81 | 2 | 2.405 | 6.681 | >0.05 |
误差 | 0.72 | 2 | 0.360 | ||
总计 | 22.16 | 8 |
项目 | 药材细颗粒 | 药材粗颗粒 | 药材饮片 |
大黄素含量(mg) | 2.03 | 1.93 | 1.72 |
浸膏干粉得率%(g/g) | 15.01(n=2) | 14.7(n=2) | 13.47(n=2) |
项目 | 药材不浸泡 | 药材浸泡0.5小时 | 药材浸泡1小时 |
大黄素含量(mg) | 1.54 | 1.76 | 1.82 |
浸膏得率%(g/g) | 12.1 | 13.4 | 13.7 |
糊精 | 淀粉 | 硫酸钙 | 磷酸氢钙 | 磷酸氢钙+淀粉 | ||
用量%(g/g) | 52 | 52 | 42 | 42 | (6+2) | (4+2) |
潮解程度 | -+ | -+ | -+ | -+ | -- | - |
75%乙醇 | 80%乙醇 | 85%乙醇 | 90%乙醇 | 95%乙醇 | |
结果 | 成团状无法制粒 | 成团状无法制粒 | 成块状粘结无法制粒 | 粘结无法制粒 | 比较松散顺利通过筛网呈颗粒状 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03131143 CN1267117C (zh) | 2003-05-14 | 2003-05-14 | 一种治疗跌打损伤、胸胁疼痛的药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03131143 CN1267117C (zh) | 2003-05-14 | 2003-05-14 | 一种治疗跌打损伤、胸胁疼痛的药物组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1457852A CN1457852A (zh) | 2003-11-26 |
CN1267117C true CN1267117C (zh) | 2006-08-02 |
Family
ID=29430565
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 03131143 Expired - Lifetime CN1267117C (zh) | 2003-05-14 | 2003-05-14 | 一种治疗跌打损伤、胸胁疼痛的药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1267117C (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103293269A (zh) * | 2012-03-02 | 2013-09-11 | 迪沙药业集团有限公司 | 一种治疗血管性痴呆的中药组合物的质量控制方法 |
CN102697903A (zh) * | 2012-05-11 | 2012-10-03 | 贾晋科 | 一种用于治疗带状疱疹的药物 |
CN102861197A (zh) * | 2012-10-24 | 2013-01-09 | 王雨 | 一种治疗跌打损伤的中药组合物 |
CN103536681A (zh) * | 2013-10-25 | 2014-01-29 | 李直韩 | 一种接骨中药组合物及其制备工艺 |
-
2003
- 2003-05-14 CN CN 03131143 patent/CN1267117C/zh not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1457852A (zh) | 2003-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1857329A (zh) | 一种以生粉入药的中药组合物的制备方法 | |
CN101057925A (zh) | 接骨七厘胶囊制备工艺及其质量控制方法 | |
CN1267117C (zh) | 一种治疗跌打损伤、胸胁疼痛的药物组合物及其制备方法 | |
CN1316990C (zh) | 一种中药组合物及其制备方法和质量控制方法 | |
CN1281268C (zh) | 益气养心安神的中药组合物及其制备方法和鉴别方法 | |
CN1709341A (zh) | 一种益气健脾的药物组合物及其制备方法和用途 | |
CN1872199A (zh) | 一种中药组合物及其制备方法 | |
CN1891284A (zh) | 一种中药组合物及其制备方法和质量控制方法 | |
CN1248721C (zh) | 一种治疗虚损病的中药组合物及其质量控制方法 | |
CN100336544C (zh) | 一种具有健肤美容作用的中药组合物及其制备方法 | |
CN1931255A (zh) | 治疗血小板减少、贫血的药物及制备方法和质量控制方法 | |
CN1437982A (zh) | 一种治疗支原体肺炎的药物组合物及其制备方法和质量控制方法 | |
CN1682969A (zh) | 一种药物组合物及其制备方法和质量控制方法 | |
CN101856381A (zh) | 一种治疗妇女更年期综合症药物制剂的制备方法及质量控制方法 | |
CN1899569A (zh) | 一种治疗声带小结、声带息肉症状的中药制备工艺及其用途 | |
CN1876000A (zh) | 治疗乳腺增生的岩鹿乳康药物制剂及制法和质量控制方法 | |
CN1586612A (zh) | 一种治疗血瘀证的颗粒剂的制备方法及质量控制方法 | |
CN1258372C (zh) | 治疗肠易激综合症的中药组合物及其制备方法 | |
CN1857385A (zh) | 一种治疗颈椎病的药物组合物及其制备方法 | |
CN1323700C (zh) | 一种治疗虚损病的中药组合物及其制备方法和质量标准 | |
CN1907321A (zh) | 一种治疗表虚不固的药物组合物及其制备工艺 | |
CN1615959A (zh) | 治疗皮肤疾病的中药胶囊制剂 | |
CN1241586C (zh) | 一种中药组合物及制备方法、质量控制方法和用途 | |
CN101036709A (zh) | 一种用于治疗妇科疾病的中药制剂及其制备方法 | |
CN110448649A (zh) | 清瘟败毒颗粒的制备工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: YU HUI Free format text: FORMER OWNER: JUXIAOPING Effective date: 20080926 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20080926 Address after: Shaanxi city of Xianyang province Baoquan Road No. 3, Lai Choi Lai Choi Tianxi room 1016 square Patentee after: Yu Hui Address before: Jiangsu Jiangdu box 01015 Yangzhou Zhonghui group Patentee before: Ju Xiaoping |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20031126 Assignee: YANGLING CHARISMA BIO-PHARMACEUTICAL Co.,Ltd. Assignor: Yu Hui Contract record no.: 2019990000184 Denomination of invention: Chinese medicine composition for curing traumatic injury and pains in chest and hypochondrium and its preparing method Granted publication date: 20060802 License type: Exclusive License Record date: 20190603 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210831 Address after: 710000 floor 29, block B, Licai Jinfangyuan Plaza, No. 29, Renmin West Road, Qindu District, Xianyang City, Shaanxi Province Patentee after: Shaanxi Li Cai Pharmaceutical Co.,Ltd. Address before: 712021 room 1016, Licai Tianxi, Licai Plaza, No. 3, Baoquan Road, Xianyang City, Shaanxi Province Patentee before: Yu Hui |
|
TR01 | Transfer of patent right | ||
CX01 | Expiry of patent term |
Granted publication date: 20060802 |
|
CX01 | Expiry of patent term |